Cancer trial drug may work differently than scientists believed, raising concerns for clinical research

Cancer trial drug may work differently than scientists believed, raising concerns for clinical research

A cancer drug currently being tested in patients may have entered clinical trials based on an incorrect understanding of how it works, according to a new study led by the University of Sydney in collaboration with Goethe University, Oxford University and the Institute of Cancer Research, London.

Scientists identify unexpected target for cancer drug

A cancer drug currently being tested in patients may not work in the way scientists originally thought, a new study suggests.  The drug, known as zavondemstat, was developed to target KDM4, a group of proteins that can help cancer cells grow and spread.  But researchers from the University of Sydney found the drug works mainly […]

Cancer Drug in Clinical Trials May Work Through an Entirely Different

A new study finds the experimental cancer drug zavondemstat and the research compound QC6352 act mainly by blocking the enzyme DHODH rather than their intended KDM4 target, raising concerns about clinical trials and years of published research.